Nuvectis Pharma (NVCT)
(Delayed Data from NSDQ)
$6.46 USD
+0.16 (2.54%)
Updated Aug 13, 2024 04:00 PM ET
After-Market: $6.54 +0.08 (1.24%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Brokerage Reports
Nuvectis Pharma, Inc. [NVCT]
Reports for Purchase
Showing records 41 - 60 ( 68 total )
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
3Q22 Results; Pipeline Progressing as Planned; NXP800 Phase 1b Expansion in 1Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Certain Biomarkers May Indicate Increased NXP900 Utility Versus Dasatinib
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Biomarker Analysis of NXP800 Supports Clinical Trials ARID1A Mutants
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
NXP800 Effective in a Xenograft Model of ARID1a-Mutated Gastric Carcinoma
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
NXP800 Shows More Promise for Gastric and Ovarian Cancers; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
2Q22 Results; Asset Development Continues As Planned Across Programs; NXP-800 Dose-Expansion Expected To Begin 1Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
2Q22: Well Funded to Advance NXP800 and NXP900
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
NXP800 IND Cleared, Allowing U.S. Sites to Participate in Phase 1a Trial
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
The U.S. Welcomes NXP800 to the Clinic; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
NXP-900 Therapeutic Potential Expands to Pediatric Medulloblastoma
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Animal Xenograft Model Shows NXP900 Antitumor Utility in Medulloblastoma
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
1Q22: Early Stage Clinical Pipeline But Solid Evidence Predicting Efficacy
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J